Sitagliptin, a once-daily, oral, potent, and highly selective DPP-4 inhibitor, inhibits plasma DPP-4 activity ≥80% over 24 h with single doses of ≥100 mg. [10] In patients with type 2 diabetes ...

Learn about the dosages of Januvia for treating type 2 diabetes. You can also find information on the drug’s strengths, form, and more.

NEW ORLEANS, March 23, 2019 /PRNewswire/ -- Oral semaglutide 7 mg and 14 mg demonstrated superior HbA 1c and body weight reductions compared to Januvia ® (sitagliptin 100 mg). Non-inferiority for ...

Compared with sitagliptin 100 mg, canagliflozin 300 mg demonstrated superior diabetes-related quality measure attainment including glycemic, BP, and weight-related quality measures.

Objectives: To compare 1-year clinical outcomes and cost efficiency of treating adults with type 2 diabetes mellitus (T2DM) with canagliflozin (300 mg/day) or sitagliptin (100 mg/day), both added ...

Merck announced that the FDA has approved Janumet XR (sitagliptin/metformin HCl extended-release tablets) for the treatment of type 2 diabetes.

Januvia is a prescription drug used to help treat type 2 diabetes in adults. Learn how to find savings, lower long-term costs, and more.

Long-acting exenatide likely will become an important new option for managing patients with type 2 diabetes.

The FDA has approved a fixed-dose combination tablet consisting of sitagliptin and simvastatin, two drugs previously approved for type 2 diabetes and hypercholesterolemia. The new drug will be ...

EASD Annual Meeting Patients with type 2 diabetes who were assigned to liraglutide reported greater treatment satisfaction when compared with patients assigned to oral sitagliptin. Researchers ...

Bagsværd, Denmark, 20 June 2018 - Novo Nordisk today announced the successful completion and headline results of the phase 3a trials PIONEER 4 comparing oral semaglutide as a treatment for adults ...